Collegium Pharmaceuticals is a pharmaceutical company focused on pain management. Co.'s portfolio includes Xtampza extended-release oxycodone, which has been approved for the management of pain; Nucynta extended-release, which is an extended-release formulation of tapentadol that is indicated for the management of pain as well as for management of the neuropathic pain associated with diabetic peripheral neuropathy; and Nucynta immediate-release, which is an immediate-release formulation of tapentadol that is indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults. The COLL stock yearly return is shown above.
The yearly return on the COLL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the COLL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|